Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
HODO-2224 by Hyundai Pharma for Cardiovascular Disease: Likelihood of Approval
HODO-2224 is under clinical development by Hyundai Pharma and currently in Phase I for Cardiovascular Disease. According to GlobalData, Phase...